UBS analyst Danielle Antalffy assumed coverage of Intuitive Surgical with a Neutral rating and $278 price target as part of a sector note on U.S. Medical Supplies and Devices. While Intuitive is one of the few true growth stocks in large-cap MedTech, the firm doesn’t have a clear view into estimate upside with what it sees as prolonged or delayed purchasing cycles in this tough macroeconomic environment, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ISRG:
- Intuitive Surgical initiated with a Neutral at UBS
- Evercore says Intuitive Surgical outperformance tied to new system speculation
- Prescription for Profit: 3 “Strong Buy” Healthcare Stocks Analysts Love
- William Blair starts Intuitive Surgical at Outperform on favorable risk/reward
- Intuitive Surgical initiated with an Outperform at William Blair